Eric C. Leuthardt, MD
- Neurosurgery
- Brain Tumors
- English
Appointments
Sees Patients For
Brain Laser Center, neuro-oncology, spine surgery, brain tumors, brain tumors requiring motor and speech mapping, surgical treatment of epilepsy, Monteris laser ablation and Gamma Knife
Hospital Affiliations
- Barnes-Jewish Hospital
- St. Louis Children's Hospital
Locations
- Center for Advanced Medicine Neuroscience Center4921 Parkview PlaceSt. Louis, MO 63110Suite: CFloor: 6Fax: (314) 362-2107Appointments:
Experience
Board Certifications
- Neurological Surgery
Academic Title(s)
Shi H. Huang Professor of NeurosurgeryProfessor, Neurosurgery, Neuroscience, Biomedical Engineering and Mechanical Engineering and Materials Science
Chief, Division of Neurotechnology
Director, Center for Innovation in Neuroscience and Technology
Director, Brain Laser Center
Vice-Chair of Innovation, Department of Neurosurgery
Research Interests
Dr. Leuthardt’s research has focused on brain computer interfaces and brain mapping – using engineering approaches to decode the brain to create novel diagnostics and treatments for diseases ranging from brain tumors, stroke, chronic pain and spinal cord injury. Dr. Leuthardt uses an integrated approach by employing multiple domains of expertise ranging from biomedical engineering, clinical neurosurgery, mathematical modeling, complex signal analysis, and computer programming. In addition to numerous peer-reviewed publications, Leuthardt has numerous patents on file with the U.S. Patent and Trademark Office for medical devices and brain computer interface technologies. Neuroprosthetics – devices linked to the brain that may lead to cures for paralysis, allow patients to move artificial limbs or restore other neurological functions.
Publications & Research
View research profile »Education
2006 Spine and Epilepsy, Department of Neurosurgery, University of Washington School of Medicine and Harborview Medical Center, Seattle, Washington
2005 Neurological Surgery, Barnes-Jewish Hospital & Washington University School of Medicine, St Louis, Missouri
2005 Neurological Surgery, Barnes-Jewish Hospital & Washington University School of Medicine, St. Louis, Missouri
1999 University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
1995 Biology and Theology, Saint Louis University, St. Louis, Missouri.
- ACERA
- Equity: Yes
- Reporting Date: 05/01/2023
- Caeli Vascular
- Equity: Yes
- Reporting Date: 05/01/2023
- Inflexion Vascular
- Equity: Yes
- Reporting Date: 05/01/2023
- Inner Cosmos
- Equity: Yes
- Reporting Date: 05/01/2023
- Kinexus
- Equity: Yes
- Reporting Date: 05/01/2023
- NeuroDev
- Equity: Yes
- Reporting Date: 05/01/2023
- Neurolutions
- Equity: Yes
- Reporting Date: 05/01/2023
- Osteovantage
- Equity: Yes
- Reporting Date: 05/01/2023
- Petal Surgical
- Equity: Yes
- Reporting Date: 05/01/2023
- Sora Imaging Solutions
- Equity: Yes
- Reporting Date: 05/01/2023
- SympEl
- Equity: Yes
- Reporting Date: 05/01/2023
Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.